NAT-EVEROLIMUS
Identification of Nat-Everolimus
| No description |
Google image searchProduct monograph
Active ingredient
everolimus, 5 MG
DIN: 02530104
Dosage form(s): TABLET
Route(s) of administration: ORAL
Schedule: Prescription
Company: NATCO PHARMA (CANADA) INC
Date: 05-APR-2023
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AH — Mammalian target of rapamycin (mTOR) kinase inhibitors (ATC, ATC/DDD)
- L04AH02 — EVEROLIMUS (ATC/DDD)
Reference brand drug: Afinitor
